# A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy

> **NCT07668804** · PHASE1,PHASE2 · RECRUITING · sponsor: **Theratocular Biotek Co.** · enrollment: 31 (estimated)

## Conditions studied

- Geographic Atrophy Due to Age-Related Macular Degeneration

## Interventions

- **DRUG:** TO-O-1007 (low-dose)
- **DRUG:** TO-O-1007 (high-dose)
- **PROCEDURE:** Sham injection

## Key facts

- **NCT ID:** NCT07668804
- **Lead sponsor:** Theratocular Biotek Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-02
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07668804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07668804, "A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07668804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*